Login to Your Account

Judge to Sandoz: No Sidestepping Biosimilar Patent Dance

By Mari Serebrov
Washington Editor

Friday, November 15, 2013
A federal judge cut short the first patent dance involving a biosimilar, calling it premature. Judge Maxine Chesney denied Sandoz Inc.’s request for declaratory judgment that the Enbrel (etanercept) biosimilar it’s developing doesn’t infringe two patents owned by Roche AG and exclusively licensed to Amgen Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription